Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.

Gavin PJ, Suseno MT, Thomson RB Jr, Gaydos JM, Pierson CL, Halstead DC, Aslanzadeh J, Brecher S, Rotstein C, Brossette SE, Peterson LR.

Antimicrob Agents Chemother. 2006 Jun;50(6):2244-7.

2.

Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial Outbreak.

Fujita A, Kimura K, Yokoyama S, Jin W, Wachino J, Yamada K, Suematsu H, Yamagishi Y, Mikamo H, Arakawa Y.

PLoS One. 2015 Nov 5;10(11):e0142366. doi: 10.1371/journal.pone.0142366. eCollection 2015.

3.

Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.

Peterson LR.

Clin Microbiol Infect. 2008 Jan;14 Suppl 1:181-4. Review. Erratum in: Clin Microbiol Infect. 2008 May;14 Suppl 5:21-4.

4.

Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.

López-Cerero L, Picón E, Morillo C, Hernández JR, Docobo F, Pachón J, Rodríguez-Baño J, Pascual A.

Clin Microbiol Infect. 2010 Feb;16(2):132-6. doi: 10.1111/j.1469-0691.2009.02893.x. Epub 2009 Jul 15.

5.

Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.

Raveh D, Yinnon AM, Broide E, Rudensky B.

Chemotherapy. 2007;53(3):185-9. Epub 2007 Mar 7.

PMID:
17347564
6.

Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.

Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE; Antibacterial Resistance Leadership Group.

Clin Infect Dis. 2015 May 1;60(9):1319-25. doi: 10.1093/cid/civ003. Epub 2015 Jan 13. Erratum in: Clin Infect Dis. 2015 Jul 1;61(1):143.

8.

Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.

Bishara J, Livne G, Ashkenazi S, Levy I, Pitlik S, Ofir O, Lev B, Samra Z.

Isr Med Assoc J. 2005 May;7(5):298-301.

9.

The impact of the increased use of piperacillin/tazobactam on the selection of antibiotic resistance among invasive Escherichia coli and Klebsiella pneumoniae isolates.

Lee J, Oh CE, Choi EH, Lee HJ.

Int J Infect Dis. 2013 Aug;17(8):e638-43. doi: 10.1016/j.ijid.2013.01.030. Epub 2013 Mar 21.

10.

Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).

Sader HS, Farrell DJ, Flamm RK, Jones RN.

J Infect. 2014 Sep;69(3):266-77. doi: 10.1016/j.jinf.2014.04.004. Epub 2014 Apr 26.

PMID:
24780763
11.

Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.

Petrikkos G, Markogiannakis A, Papaparaskevas J, Daikos GL, Stefanakos G, Zissis NP, Avlamis A.

Int J Antimicrob Agents. 2007 Jan;29(1):34-8. Erratum in: Int J Antimicrob Agents. 2007 Sep;30(3):287. Papapareskevas Joseph [corrected to Papaparaskevas, Joseph].

PMID:
17189092
12.

In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli.

[No authors listed]

Clin Infect Dis. 2013 Nov;57(10):iii-iv. No abstract available.

PMID:
24308040
13.

Efficacy of a Ceftazidime-Avibactam combination in a murine model of Septicemia caused by Enterobacteriaceae species producing ampc or extended-spectrum β-lactamases.

Levasseur P, Girard AM, Lavallade L, Miossec C, Pace J, Coleman K.

Antimicrob Agents Chemother. 2014 Nov;58(11):6490-5. doi: 10.1128/AAC.03579-14. Epub 2014 Aug 18.

14.

Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.

Retamar P, López-Cerero L, Muniain MA, Pascual Á, Rodríguez-Baño J; ESBL-REIPI/GEIH Group.

Antimicrob Agents Chemother. 2013 Jul;57(7):3402-4. doi: 10.1128/AAC.00135-13. Epub 2013 Apr 22.

15.

Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.

Seo YB, Lee J, Kim YK, Lee SS, Lee JA, Kim HY, Uh Y, Kim HS, Song W.

BMC Infect Dis. 2017 Jun 7;17(1):404. doi: 10.1186/s12879-017-2502-x.

17.

In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae.

Harada Y, Morinaga Y, Kaku N, Nakamura S, Uno N, Hasegawa H, Izumikawa K, Kohno S, Yanagihara K.

Clin Microbiol Infect. 2014 Nov;20(11):O831-9. doi: 10.1111/1469-0691.12677. Epub 2014 Jun 14.

18.

Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests.

Marchaim D, Sunkara B, Lephart PR, Gudur UM, Bhargava A, Mynatt RP, Zhao JJ, Bheemreddy S, Hayakawa K, Chopra T, Dhar S, Kaye KS.

Infect Control Hosp Epidemiol. 2012 Aug;33(8):853-5. doi: 10.1086/666632. Epub 2012 Jun 11. No abstract available.

PMID:
22759556
19.
20.

In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae.

Titelman E, Karlsson IM, Ge Y, Giske CG.

Diagn Microbiol Infect Dis. 2011 May;70(1):137-41. doi: 10.1016/j.diagmicrobio.2011.02.004.

PMID:
21513849

Supplemental Content

Support Center